U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07551414) titled 'Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI' on April 17.
Brief Summary: A Prospective Study of Zorifertinib Combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy for Leptomeningeal Progression in NSCLC Patients After Third-Generation EGFR-TKI Therapy
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
NSCLC (Non-small Cell Lung Carcinoma)
Leptomeningeal Metastasis
EGFR-TKI Sensitizing Mutation
Zorifertinib
Intervention:
DRUG: Zorifertinib Plus Intra-Ommaya CSF Chemotherapy
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy fo...